Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 736

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 736
---
 |     |    — |     |     — |     |  P_II |     |  P_II |     |  P_II |     |  P_II |     |  P_II |     |  P_II |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |
| Phase III          |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     | P_III |     | P_III |     | P_III |     | P_III |     | P_III |     | P_III |     | P_III |     | P_III |     |     — |     |     — |     |     — |
| Sales              |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     | Sales |     | Sales |

| Moore Financial Consulting |

Annex E-22

Total Available Markets AstroRx ® According to the Company, the AstroRx ®is for the treatment of all ALS patients, although it is probable that it will be more efficient when given to patients that are in the early stages of the illness. The total available market therefore comprises every case of ALS. We have assumed that the relevant markets for the Company in the first years